NO20041802L - Antistoffer mot human vevsfaktor - Google Patents

Antistoffer mot human vevsfaktor

Info

Publication number
NO20041802L
NO20041802L NO20041802A NO20041802A NO20041802L NO 20041802 L NO20041802 L NO 20041802L NO 20041802 A NO20041802 A NO 20041802A NO 20041802 A NO20041802 A NO 20041802A NO 20041802 L NO20041802 L NO 20041802L
Authority
NO
Norway
Prior art keywords
antibodies
human tissue
tissue factor
factor
human
Prior art date
Application number
NO20041802A
Other languages
English (en)
Norwegian (no)
Inventor
Per-Ola Freskgaard
Jes Thorn Clausen
Brit Binow Sorensen
Marianne Kjalke
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of NO20041802L publication Critical patent/NO20041802L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO20041802A 2001-10-02 2004-04-30 Antistoffer mot human vevsfaktor NO20041802L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200101437 2001-10-02
PCT/DK2002/000644 WO2003029295A1 (en) 2001-10-02 2002-09-30 Human tissue factor antibodies

Publications (1)

Publication Number Publication Date
NO20041802L true NO20041802L (no) 2004-04-30

Family

ID=8160743

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20041802A NO20041802L (no) 2001-10-02 2004-04-30 Antistoffer mot human vevsfaktor

Country Status (15)

Country Link
EP (1) EP1434802A1 (cs)
JP (1) JP2005512970A (cs)
KR (1) KR20040045478A (cs)
CN (1) CN1575302A (cs)
BR (1) BR0213046A (cs)
CA (1) CA2460917A1 (cs)
CZ (1) CZ2004454A3 (cs)
HU (1) HUP0401658A2 (cs)
IL (1) IL160998A0 (cs)
MX (1) MXPA04003051A (cs)
NO (1) NO20041802L (cs)
PL (1) PL368989A1 (cs)
RU (1) RU2004113373A (cs)
WO (1) WO2003029295A1 (cs)
ZA (1) ZA200402303B (cs)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060235209A9 (en) 1997-03-10 2006-10-19 Jin-An Jiao Use of anti-tissue factor antibodies for treating thromboses
US20030109680A1 (en) 2001-11-21 2003-06-12 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US5986065A (en) 1997-03-10 1999-11-16 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US7749498B2 (en) 1997-03-10 2010-07-06 Genentech, Inc. Antibodies for inhibiting blood coagulation and methods of use thereof
WO2002078738A1 (fr) * 2001-03-26 2002-10-10 Koji Suzuki Agents ameliorant la rheologie sanguine
AU2003277832A1 (en) * 2002-10-31 2004-05-25 Novo Nordisk A/S Humanized tissue factor antibodies
EP1587549A2 (en) * 2003-01-22 2005-10-26 Novo Nordisk A/S Radiolabelled tissue factor binding agent and the use thereof
US7605235B2 (en) 2003-05-30 2009-10-20 Centocor, Inc. Anti-tissue factor antibodies and compositions
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
EP1633309A4 (en) * 2003-05-30 2007-06-13 Centocor Inc METHOD FOR INHIBITING TUMOR GROWTH WITH ANTI-TISSUE FACTOR ANTIBODIES
WO2005004793A2 (en) * 2003-06-19 2005-01-20 Tanox Inc. Compositions and methods for treating coagulation related disorders
WO2005020927A2 (en) * 2003-08-29 2005-03-10 Centocor, Inc. Method of promoting graft survival with anti-tissue factor antibodies
JP2007523099A (ja) * 2004-02-20 2007-08-16 ノボ　ノルディスク　アクティーゼルスカブ 組み合わせ療法
EP3524685B1 (en) 2006-09-08 2021-11-03 AbbVie Bahamas Ltd. Interleukin -13 binding proteins
CN101423552B (zh) * 2008-02-29 2012-05-16 复旦大学 一种人源抗人组织因子Fab及其制备方法
AU2013203150B2 (en) * 2008-12-09 2016-09-22 Genmab A/S Human antibodies against tissue factor
UA109633C2 (uk) * 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
AU2016277670B2 (en) * 2008-12-09 2019-02-07 Genmab A/S Human antibodies against tissue factor
WO2010131235A1 (en) * 2009-05-15 2010-11-18 University Of The Free State Inhibitory antibody fragments to human tissue factor
HUE035599T2 (en) 2010-06-15 2018-05-28 Genmab As Human antibody drug conjugates against tissue factor
US8722044B2 (en) 2011-03-15 2014-05-13 Janssen Biotech, Inc. Human tissue factor antibody and uses thereof
WO2017028823A1 (zh) * 2015-08-20 2017-02-23 复旦大学 靶向于组织因子的抗体、其制备方法和用途
WO2018036117A1 (zh) * 2016-08-22 2018-03-01 复旦大学 靶向于组织因子的抗体、其制备方法和用途
CN106938051B (zh) 2016-08-22 2019-10-11 复旦大学 靶向于组织因子的抗体-药物偶联物
TWI841554B (zh) 2018-03-21 2024-05-11 丹麥商珍美寶股份有限公司 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法
MX2020011823A (es) 2018-05-07 2021-03-29 Genmab As Metodos para tratar cancer con combinacion de anticuerpo anti-muerte programada-1 (pd-1) y conjugado de anticuerpo anti-factor de tejido y farmaco.
TWI844571B (zh) 2018-10-30 2024-06-11 丹麥商珍美寶股份有限公司 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001978A (en) * 1987-03-31 1999-12-14 The Scripps Research Institute Human tissue factor related DNA segments polypeptides and antibodies
US5223427A (en) * 1987-03-31 1993-06-29 The Scripps Research Institute Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain
JP2779193B2 (ja) * 1989-02-02 1998-07-23 帝人株式会社 抗ヒト組織因子モノクローナル抗体
ES2231817T3 (es) * 1995-06-07 2005-05-16 Ortho-Mcneil Pharmaceutical, Inc. Anticuerpos del factor anti-tejido injertados a cdr y procedimientos de uso de los mismos.
AU752730B2 (en) * 1998-04-03 2002-09-26 Chugai Seiyaku Kabushiki Kaisha Humanized antibody against human tissue factor (TF) and process for constructing humanized antibody
KR20030008205A (ko) * 1999-10-01 2003-01-24 추가이 세이야쿠 가부시키가이샤 혈액응고 관련 질환의 예방 및 치료
HK1049184A1 (zh) * 2000-03-16 2003-05-02 Genentech, Inc. 具有增强抗凝血效能的抗组织因子抗体

Also Published As

Publication number Publication date
ZA200402303B (en) 2004-11-25
WO2003029295A1 (en) 2003-04-10
EP1434802A1 (en) 2004-07-07
PL368989A1 (en) 2005-04-04
RU2004113373A (ru) 2005-03-27
CA2460917A1 (en) 2003-04-10
BR0213046A (pt) 2005-06-28
JP2005512970A (ja) 2005-05-12
CN1575302A (zh) 2005-02-02
IL160998A0 (en) 2004-08-31
MXPA04003051A (es) 2004-07-05
CZ2004454A3 (cs) 2004-09-15
HUP0401658A2 (hu) 2004-11-29
KR20040045478A (ko) 2004-06-01

Similar Documents

Publication Publication Date Title
NO20041802L (no) Antistoffer mot human vevsfaktor
NO20023266D0 (no) Antistoffer mot humant IL-1
NO20026063L (no) Antistoffer mot human MCP-1
NO20004133D0 (no) Antistoffer mot human CD40
DK1313769T3 (da) Antistoffer mod humant IL-1beta
NO20042388L (no) Antistoff mot CD40
NO20034554D0 (no) Antistoffer mot VLA-1
NO20041018L (no) Antistoffer mot OPGL
IS6779A (is) Mannlíkt mótefni gegn LT-beta-R
IS8266A (is) Breytt mennsk IGF-1R mótefni
EP1506286A4 (en) NEUTRALIZATION OF A HUMAN ANTI-IGFR ANTIBODY
DK1572946T3 (da) Terapeutisk humant monoklonalt anti-IL-1R1-antistof
FI20000416L (fi) Ihmiselimistöön liittyvä mittaus
DE60118511D1 (de) Blutsammelsatz
NO20054170D0 (no) Antistoff mot human IL-21 reseptor og anvendelser derav
DE60324178D1 (de) THIAZOLIDIN-4-ONES UM hYAK3 PROTEINEN ZU HEMMEN
EP1448787A4 (en) HUMAN MONOCLONAL ANTIBODIES DIRECTED AGAINST DENDRITIC CELLS
DE60221143D1 (de) Brusteinlage enthaltend hautpflegemittel
DE60205514D1 (de) Wegwerfwindel
DE60211241D1 (de) Zusammengesetzte Damenbinde
ATE553129T1 (de) Antikörper gegen humanes il-12
DE60112705T2 (de) Blutsammelsatz
ATE258035T1 (de) Wegwerfartikel für menschliche fäkalien
EP1646401A4 (en) SPECIFIC HUMAN ANTIBODIES
AR028262A1 (es) Anticuerpos especificos de fap-alfa humanos

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application